Relevance and potential of sphingosine-1-phosphate in vascular inflammatory disease

Biological Chemistry

Volumn 389, Issue 11, 2008, Pages 1381-1390

  Van Der Giet, Markus ^a   Tölle, Markus ^a   Kleuser, Burkhard ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Atherosclerosis; FTY720; S1P receptors; Sphingosine 1 phosphate; Vascular inflammation

Indexed keywords

5 (4 PHENYL 5 TRIFLUOROMETHYL 2 THIENYL) 3 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 OXADIAZOLE; FINGOLIMOD; G PROTEIN COUPLED RECEPTOR; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE 1 RECEPTOR; SPHINGOSINE 1 PHOSPHATE 2 RECEPTOR; SPHINGOSINE 1 PHOSPHATE 3 RECEPTOR; SPHINGOSINE 1 PHOSPHATE 4 RECEPTOR; SPHINGOSINE 1 PHOSPHATE 5 RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BLOOD VESSEL TONE; CELL ADHESION; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; DISEASE COURSE; ENDOTHELIUM CELL; HUMAN; INFLAMMATORY DISEASE; INHIBITION KINETICS; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SMOOTH MUSCLE FIBER; VASCULAR DISEASE;

ANIMALS; ATHEROSCLEROSIS; BLOOD VESSELS; ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; LYSOPHOSPHOLIPIDS; MYOCYTES, SMOOTH MUSCLE; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE;

EID: 56549124801     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2008.165     Document Type: Review

References (86)

1. Alewijnse, A.E., Peters, S.L., and Michel, M.C. (2004). Cardiovascular effects of sphingosine-1-phosphate and other sphingomyelin metabolites. Br. J. Pharmacol. 143, 666-684.
2. Allende, M.L., and Proia, R.L. (2002). Sphingosine-1-phosphate receptors and the development of the vascular system. Biochim. Biophys. Acta 1582, 222-227.
3. Allende, M.L., Dreier, J.L., Mandala, S., and Proia, R.L. (2004). Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J. Biol. Chem. 279, 15396-15401.
4. Awad, A.S., Ye, H., Huang, L., Li, L., Foss, F.W. Jr., Macdonald, T.L., Lynch, K.R., and Okusa, M.D. (2006). Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am. J. Physiol. Renal Physiol. 290, F1516-1524.
5. Baudhuin, L.M., Jiang, Y., Zaslavsky, A., Ishii, I., Chun, J., and Xu, Y. (2004). S1P3-mediated Akt activation and cross-talk with platelet-derived growth factor receptor (PDGFR). FASEB J. 18, 341-343.
6. Baumruker, T., Billich, A., and Brinkmann, V. (2007). FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis. Expert Opin. Investig. Drugs 16, 283-289.
7. Berliner, J.A., Navab, M., Fogelman, A.M., Frank, J.S., Demer, L.L., Edwards, P.A., Watson, A.D., and Lusis, A.J. (1995). Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 91, 2488-2496.
8. Birgbauer, E. and Chun, J. (2006). New developments in the biological function of lysophospholipids. Cell. Mol. Life Sci. 63, 2695-2701.
9. Bischoff, A., Czyborra, P., Meyer Zu Heringdorf, D., Jakobs, K.H., and Michel, M.C. (2000). Sphingosine-1-phosphate reduces rat renal and mesenteric blood flow in vivo in a pertussis toxin-sensitive manner. Br. J. Pharmacol. 130, 1878-1883.
10. Bolick, D.T., Srinivasan, S., Kim, K.W., Hatley, M.E., Clemens, J.J., Whetzel, A., Ferger, N., Macdonald, T.L., Davis, M.D., Tsao, P.S., et al. (2005). Sphingosine-1-phosphate prevents tumor necrosis factor-α-mediated monocyte adhesion to aortic endothelium in mice. Arterioscler. Thromb. Vasc. Biol. 25, 976-981.
11. Brinkmann, V. and Lynch, K.R. (2002). FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr. Opin. Immunol. 14, 569-575.
12. Butler, J., Lana, D., Round, O., and LaMontagne, K. (2004). Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells. Prostaglandins Other Lipid Mediat. 73, 29-45.
13. Chae, S.S., Paik, J.H., Furneaux, H., and Hla, T. (2004). Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference. J. Clin. Invest. 114, 1082-1089.
14. Chun, J., Contos, J.J., and Munroe, D. (1999). A growing family of receptor genes for lysophosphatidic acid (LPA) and other lysophospholipids (LPs). Cell Biochem. Biophys. 30, 213-242.
15. Chun, J., Goetzl, E.J., Hla, T., Igarashi, Y., Lynch, K.R., Moolenaar, W., Pyne, S., and Tigyi, G. (2002). International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol. Rev. 54, 265-269.
16. Coussin, F., Scott, R.H., Wise, A., and Nixon, G.F. (2002). Comparison of sphingosine 1-phosphate-induced intracellular signaling pathways in vascular smooth muscles: differential role in vasoconstriction. Circ. Res. 91, 151-157.
17. Garcia, J.G., Liu, F., Verin, A.D., Birukova, A., Dechert, M.A., Gerthoffer, W.T., Bamberg, J.R., and English, D. (2001). Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J. Clin. Invest. 108, 689-701.
18. Gardell, S.E., Dubin, A.E., and Chun, J. (2006). Emerging medicinal roles for lysophospholipid signaling. Trends Mol. Med. 12, 65-75.
19. Gerrity, R.G. (1981). The role of the monocyte in atherogenesis: II. Migration of foam cells from atherosclerotic lesions. Am. J. Pathol. 103, 191-200.
20. Hahn, B.H., Grossman, J., Chen, W., and McMahon, M. (2007). The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J. Autoimmun. 28, 69-75.
21. Hla, T. (2004). Physiological and pathological actions of sphingosine 1-phosphate. Semin. Cell Dev. Biol. 15, 513-520.
22. Hla, T. and Maciag, T. (1990). An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein-coupled receptors. J. Biol. Chem. 265, 9308-9313.
23. Hla, T., Lee, M.J., Ancellin, N., Paik, J.H., and Kluk, M.J. (2001). Lysophospholipids - receptor revelations. Science 294, 1875-1878.
24. Huo, Y. and Ley, K. (2001). Adhesion molecules and atherogenesis. Acta Physiol. Scand. 173, 35-43.
25. Hwang, M.W., Matsumori, A., Furukawa, Y., Ono, K., Okada, M., Iwasaki, A., Hara, M., and Sasayama, S. (1999). FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation. Circulation 100, 1322-1329.
26. Inoki, I., Takuwa, N., Sugimoto, N., Yoshioka, K., Takata, S., Kaneko, S., and Takuwa, Y. (2006). Negative regulation of endothelial morphogenesis and angiogenesis by S1P2 receptor. Biochem. Biophys. Res. Commun. 346, 293-300.
27. Ishii, I., Fukushima, N., Ye, X., and Chun, J. (2004). Lysophospholipid receptors: signaling and biology. Annu. Rev. Biochem. 73, 321-354.
28. Kappos, L., Antel, J., Comi, G., Montalban, X., O'Connor, P., Polman, C.H., Haas, T., Korn, A.A., Karlsson, G., and Radue, E.W. (2006). Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 355, 1124-1140.
29. Kawata, T., Ishizuka, T., Tomura, H., Hisada, T., Dobashi, K., Tsukagoshi, H., Ishiwara, M., Kurose, H., Mori, M., and Okajima, F. (2005). Sphingosine 1-phosphate inhibits migration and RANTES production in human bronchial smooth muscle cells. Biochem. Biophys. Res. Commun. 331, 640-647.
30. Keul, P., Tolle, M., Lucke, S., von Wnuck Lipinski, K., Heusch, G., Schuchardt, M., van der Giet, M., and Levkau, B. (2007). The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 27, 607-613.
31. Kimura, T., Sato, K., Malchinkhuu, E., Tomura, H., Tamama, K., Kuwabara, A., Murakami, M., and Okajima, F. (2003). High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler. Thromb. Vasc. Biol. 23, 1283-1288.
32. Klingenberg, R., Nofer, J.R., Rudling, M., Bea, F., Blessing, E., Preusch, M., Grone, H.J., Katus, H.A., Hansson, G.K., and Dengler, T.J. (2007). Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 27, 2392-2399.
33. Kluk, M.J. and Hla, T. (2001). Role of the sphingosine 1-phosphate receptor EDG-1 in vascular smooth muscle cell proliferation and migration. Circ. Res. 89, 496-502.
34. Kono, M., Mi, Y., Liu, Y., Sasaki, T., Allende, M.L., Wu, Y.P., Yamashita, T., and Proia, R.L. (2004). S1P1, S1P2 and S1P3 receptors coordinately function during embryonic angiogenesis. J. Biol. Chem. 279, 29367-29373.
35. Krump-Konvalinkova, V., Yasuda, S., Rubic, T., Makarova, N., Mages, J., Erl, W., Vosseler, C., Kirkpatrick, C.J., Tigyi, G., and Siess, W. (2005). Stable knock-down of the sphingosine 1-phosphate receptor S1P1 influences multiple functions of human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 25, 546-552.
36. Krump-Konvalinkova, V., Chwalla, I., and Siess, W. (2008). FTY720 inhibits S1P-mediated endothelial healing: relationship to S1P(1)-receptor surface expression. Biochem. Biophys. Res. Commun. 370, 603-608.
37. Lee, M.J., Thangada, S., Claffey, K.P., Ancellin, N., Liu, C.H., Kluk, M., Volpi, M., Sha'afi, R.I., and Hla, T. (1999). Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 99, 301-312.
38. Lee, M.J., Thangada, S., Paik, J.H., Sapkota, G.P., Ancellin, N., Chae, S.S., Wu, M., Morales-Ruiz, M., Sessa, W.C., Alessi, D.R., et al. (2001). Akt-mediated phosphorylation of the G protein-coupled receptor EDG-1 is required for endothelial cell chemotaxis. Mol. Cell 8, 693-704.
39. Lee, J.F., Zeng, Q., Ozaki, H., Hand, A.R., Hla, T., Wang, E., and Lee, M.J. (2006). Dual roles of tight junction-associated protein, zonula occludens-1, in sphingosine 1-phosphate-mediated endothelial chemotaxis and barrier integrity. J. Biol. Chem. 281, 29190-29200.
40. Levkau, B., Hermann, S., Theilmeier, G., van der Giet, M., Chun, J., Schober, O., and Schafers, M. (2004). High-density lipoprotein stimulates myocardial perfusion in vivo. Circulation 110, 3355-3359.
41. Libby, P. (2002). Inflammation in atherosclerosis. Nature 420, 868-874.
42. Libby, P., Ridker, P.M., and Maseri, A. (2002). Inflammation and atherosclerosis. Circulation 105, 1135-1143.
43. Lien, Y.H., Yong, K.C., Cho, C., Igarashi, S., and Lai, L.W. (2006). S1P(1)-selective agonist, SEW2871, ameliorates ischemic acute renal failure. Kidney Int. 69, 1601-1608.
44. Limaye, V., Li, X., Hahn, C., Xia, P., Berndt, M.C., Vadas, M.A., and Gamble, J.R. (2005). Sphingosine kinase-1 enhances endothelial cell survival through a PECAM-1-dependent activation of PI-3K/Akt and regulation of Bcl-2 family members. Blood 105, 3169-3177.
45. Linn, S.C., Kim, H.S., Keane, E.M., Andras, L.M., Wang, E., and Merrill, A.H. Jr. (2001). Regulation of de novo sphingolipid biosynthesis and the toxic consequences of its disruption. Biochem. Soc. Trans. 29, 831-835.
46. Liu, Y., Wada, R., Yamashita, T., Mi, Y., Deng, C.X., Hobson, J.P., Rosenfeldt, H.M., Nava, V.E., Chae, S.S., Lee, M.J., et al. (2000). Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J. Clin. Invest. 106, 951-961.
47. iα2-linked Rho kinase activity. Am. J. Respir. Cell Mol. Biol. 24, 711-719.
48. Liu, H., Chakravarty, D., Maceyka, M., Milstien, S., and Spiegel, S. (2002). Sphingosine kinases: a novel family of lipid kinases. Prog. Nucleic Acid Res. Mol. Biol. 71, 493-511.
49. Lorenz, J.N., Arend, L.J., Robitz, R., Paul, R.J., and Maclennan, A.J. (2006). Vascular dysfunction in S1P2 sphingosine 1-phosphate receptor knockout mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292, 12440-12446.
50. Merrill, A.H. Jr., Schmelz, E.M., Dillehay, D.L., Spiegel, S., Shayman, J.A., Schroeder, J.J., Riley, R.T., Voss, K.A., and Wang, E. (1997). Sphingolipids - the enigmatic lipid class: biochemistry, physiology, and pathophysiology. Toxicol. Appl. Pharmacol. 142, 208-225.
51. Mitchell, R.N. and Libby, P. (2007). Vascular remodeling in transplant vasculopathy. Circ. Res. 100, 967-978.
52. Mizugishi, K., Yamashita, T., Olivera, A., Miller, G.F., Spiegel, S., and Proia, R.L. (2005). Essential role for sphingosine kinases in neural and vascular development. Mol. Cell. Biol. 25, 11113-11121.
53. Morales, A. and Fernandez-Checa, J.C. (2008). Pharmacological modulation of sphingolipids and role in disease and cancer cell biology. Mini Rev. Med. Chem. 8, 371-382.
54. Naghavi, M., Libby, P., Falk, E., Casscells, S.W., Litovsky, S., Rumberger, J., Badimon, J.J., Stefanadis, C., Moreno, P., Pasterkamp, G., et al. (2003a). From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 108, 1772-1778.
55. Naghavi, M., Libby, P., Falk, E., Casscells, S.W., Litovsky, S., Rumberger, J., Badimon, J.J., Stefanadis, C., Moreno, P., Pasterkamp, G., et al. (2003b). From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 108, 1664-1672.
56. Napoli, C., de Nigris, F., Williams-Ignarro, S., Pignalosa, O., Sica, V., and Ignarro, L.J. (2006). Nitric oxide and atherosclerosis: an update. Nitric Oxide 15, 265-279.
57. Nofer, J.R. and Assmann, G. (2005). The protective role of HDL. In: Lectures in Clinical Atherosclerosis and Dyslipidemia, L.A. Carlson, ed. (London, UK: Science Press), pp. 127-154.
58. Nofer, J.R., Kehrel, B., Fobker, M., Levkau, B., Assmann, G., and von Eckardstein, A. (2002). HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 161, 1-16.
59. Nofer, J.R., Geigenmuller, S., Gopfert, C., Assmann, G., Buddecke, E., and Schmidt, A. (2003). High density lipoprotein-associated lysosphingolipids reduce E-selectin expression in human endothelial cells. Biochem. Biophys. Res. Commun. 310, 98-103.
60. Nofer, J.R., van der Giet, M., Tolle, M., Wolinska, I., von Wnuck Lipinski, K., Baba, H.A., Tietge, U.J., Godecke, A., Ishii, I., Kleuser, B., et al. (2004). HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest. 113, 569-581.
61. Nofer, J.R., Bot, M., Brodde, M., Taylor, P.J., Salm, P., Brinkmann, V., van Berkel, T., Assmann, G., and Biessen, E.A. (2007). FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 115, 501-508.
62. Ohmori, T., Yatomi, Y., Osada, M., Kazama, F., Takafuta, T., Ikeda, H., and Ozaki, Y. (2003). Sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2. Cardiovasc. Res. 58, 170-177.
63. Osada, M., Yatomi, Y., Ohmori, T., Ikeda, H., and Ozaki, Y. (2002). Enhancement of sphingosine 1-phosphate-induced migration of vascular endothelial cells and smooth muscle cells by an EDG-5 antagonist. Biochem. Biophys. Res. Commun. 299, 483-487.
64. Paik, J.H., Chae, S., Lee, M.J., Thangada, S., and Hla, T. (2001). Sphingosine 1-phosphate-induced endothelial cell migration requires the expression of EDG-1 and EDG-3 receptors and Rho-dependent activation of avb3- and b1-containing integrins. J. Biol. Chem. 276, 11830-11837.
65. Rossig, L., Dimmeler, S., and Zeiher, A.M. (2001). Apoptosis in the vascular wall and atherosclerosis. Basic Res. Cardiol. 96, 11-22.
66. Salomone, S., Yoshimura, S., Reuter, U., Foley, M., Thomas, S.S., Moskowitz, M.A., and Waeber, C. (2003). S1P3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate. Eur. J. Pharmacol. 469, 125-134.
67. Salvadori, M., Budde, K., Charpentier, B., Klempnauer, J., Nashan, B., Pallardo, L.M., Eris, J., Schena, F.P., Eisenberger, U., Rostaing, L., et al. (2006). FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am. J. Transplant. 6, 2912-2921.
68. Sanchez, T., Estrada-Hernandez, T., Paik, J.H., Wu, M.T., Venkataraman, K., Brinkmann, V., Claffey, K., and Hla, T. (2003). Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J. Biol. Chem. 278, 47281-47290.
69. Sheikine, Y. and Hansson, G.K. (2004). Chemokines and atherosclerosis. Ann. Med. 36, 98-118.
70. Singer, I.I., Tian, M., Wickham, L.A., Lin, J., Matheravidathu, S.S., Forrest, M.J., Mandala, S., and Quackenbush, E.J. (2005). Sphingosine-1- phosphate agonists increase macrophage homing, lymphocyte contacts, and endothelial junctional complex formation in murine lymph nodes. J. Immunol. 175, 7151-7161.
71. Skoura, A., Sanchez, T., Claffey, K., Mandala, S.M., Proia, R.L., and Hla, T. (2007). Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina. J. Clin. Invest. 117, 2506-2516.
72. Spiegel, S. and Milstien, S. (2000). Functions of a new family of sphingosine-1-phosphate receptors. Biochim. Biophys. Acta 1484, 107-116.
73. Takuwa, Y. (2002). [Regulation of Rho family G proteins and cell motility by the Edg family of sphingosine 1-phosphate receptors]. Tanpakushitsu kakusan koso 47, 496-502 (in Japanese).
74. Tamama, K., Tomura, H., Sato, K., Malchinkhuu, E., Damirin, A., Kimura, T., Kuwabara, A., Murakami, M., and Okajima, F. (2005). High-density lipoprotein inhibits migration of vascular smooth muscle cells through its sphingosine 1-phosphate component. Atherosclerosis 178, 19-23.
75. Tanimoto, T., Jin, Z.G., and Berk, B.C. (2002). Transactivation of vascular endothelial growth factor (VEGF) receptor Flk-1/KDR is involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt and endothelial nitric-oxide synthase (eNOS). J. Biol. Chem. 277, 42997-43001.
76. Theilmeier, G., Schmidt, C., Herrmann, J., Keul, P., Schafers, M., Herrgott, I., Mersmann, J., Larmann, J., Hermann, S., Stypmann, J., et al. (2006). High-density lipoproteins and their constituent, sphingosine-1- phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 114, 1403-1409.
77. Tolle, M., Levkau, B., Keul, P., Brinkmann, V., Giebing, G., Schonfelder, G., Schafers, M., von Wnuck Lipinski, K., Jankowski, J., Jankowski, V., et al. (2005). Immunomodulator FTY720 induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3. Circ. Res. 96, 913-920.
78. Venkataraman, K., Lee, Y.M., Michaud, J., Thangada, S., Ai, Y., Bonkovsky, H.L., Parikh, N.S., Habrukowich, C., and Hla, T. (2008). Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ. Res. 102, 669-676.
79. von Eckardstein, A., Nofer, J.R., and Assmann, G. (2001). High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 21, 13-27.
80. Walter, D.H., Rochwalsky, U., Reinhold, J., Seeger, F., Aicher, A., Urbich, C., Spyridopoulos, I., Chun, J., Brinkmann, V., Keul, P., et al. (2006). Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor. Arterioscler. Thromb. Vasc. Biol. 27, 275-282.
81. Wang, F., Nobes, C.D., Hall, A., and Spiegel, S. (1997). Sphingosine 1-phosphate stimulates rho-mediated tyrosine phosphorylation of focal adhesion kinase and paxillin in Swiss 3T3 fibroblasts. Biochem. J. 324, 481-488.
82. Whetzel, A.M., Bolick, D.T., Srinivasan, S., Macdonald, T.L., Morris, M.A., Ley, K., and Hedrick, C.C. (2006). Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor. Circ. Res. 99, 731-739.
83. Xia, P., Vadas, M.A., Rye, K.A., Barter, P.J., and Gamble, J.R. (1999). High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J. Biol. Chem. 274, 33143-33147.
84. Xin, C., Ren, S., Kleuser, B., Shabahang, S., Eberhardt, W., Radeke, H., Schafer-Korting, M., Pfeilschifter, J., and Huwiler, A. (2004). Sphingosine-1-phosphate cross-activates the Smad signaling cascade and mimics TGFβ-induced cell responses. J. Biol. Chem. 279, 35255-35262.
85. Zaslavsky, A., Singh, L., Tan, H., Ding, H.A., Liang, Z., and Xu, Y. (2006). Homo- and hetero-dimerization of LPA/S1P receptors, OGR1 and GPR4. Biochim. Biophys. Acta 1761, 1200-1212.
86. Zohlnhofer, D., Klein, C.A., Richter, T., Brandl, R., Murr, A., Nuhrenberg, T., Schomig, A., Baeuerle, P.A., and Neumann, F.J. (2001). Gene expression profiling of human stent-induced neointima by cDNA array analysis of microscopic specimens retrieved by helix cutter atherectomy: detection of FK506-binding protein 12 upregulation. Circulation 103, 1396-1402.